The SGLT2 inhibitor canagliflozin: a comprehensive effect in the treatment of type 2 diabetes mellitus

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2023; 23(46): 125-126
Category: Reviews

Sources

Perkovic V, de Zeeuw D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6(9): 691–704. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(18)30141–4>.
Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.
Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
Lavelle-Gonzalez FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56(12): 2582–2592. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–013–3039–1>.
Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13(7): 669–672. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2011.01406.x>.
Jardine MJ, Mahaffey KW, Neal B et al. [CREDENCE study investigators]. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46(6): 462–472. Dostupné z DOI: <http://dx.doi.org/10.1159/000484633>.
Durkin M, Blais J. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy. Diabetes Ther 2021; 12(2): 499–508. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–020–00953–4>.
Spertus JA, Birmingham MC, Butler J et al. Novel Trial Design: CHIEF-HF. Circ Heart Fail 2021; 14(3): e007767. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.007767>. Erratum in: Circ Heart Fail 2021; 14(4): e000068. Dostupné z DOI: <http://dx.doi.org/10.1161/HHF.0000000000000068>.
Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.
Invokana. Skrátená informácia o prípravku (SPC). Dostupné z WWW: <http://www.sukl.sk>.